Person: BAŞARANOĞLU, METİN
10 results
Search Results
Now showing 1 - 10 of 10
Publication Metadata only PORTAL VEIN THROMBOSIS(2022-04-01T00:00:00Z) Başaranoğlu, Metin; BAŞARANOĞLU, METİNPublication Open Access Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease(2023-06-01) Demirel M.; Köktaşoğlu F.; Özkan E.; Dulun Ağaç H.; Gül A. Z.; Sharifov R.; Sarıkaya U.; Başaranoğlu M.; Selek Ş.; DEMİREL, METİN; KÖKTAŞOĞLU, FATMANUR; DULUN AĞAÇ, HALİME; GÜL, AYŞE ZEHRA; SARIKAYA, UFUK; BAŞARANOĞLU, METİN; SELEK, ŞAHABETTİNObjectives: Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by the accumulation of excessive fat in the liver, which can lead to fibrosis and has an increasing prevalence. NAFLD requires non-invasive diagnostic biomarkers. While typically observed in overweight individuals, it can also occur in non-obese/non-overweight individuals. Comparative studies on non-obese NAFLD patients are scarce. This study aimed to conduct a using liquid chromatography-high resolution mass spectrometry (LC-MS/MS)-based metabolic profiling of non-obese NAFLD patients and healthy controls. Materials and methods: The patient group consisted of 27 individuals with NAFLD, while the healthy control group included 39 individuals. Both groups were between 18 and 40 years old, had a BMI of less than 25 and had alcohol consumption less than 20 g/week for men and 10 g/week for women. Serum samples were collected and analyzed using LC-MS/MS. The data were analyzed using the TidyMass and MetaboAnalyst. Results: The LC-MS/MS analyses detected significant changes in D-amino acid metabolism, vitamin B6 metabolism, apoptosis, mTOR signaling pathway, lysine degradation, and phenylalanine metabolism pathways in non-obese NAFLD patients. Significant changes were also observed in the metabolites D-pantothenic acid, hypoxanthine, citric acid, citramalic acid, L-phenylalanine, glutamine, and histamine-trifluoromethyl-toluidide, β-hydroxymyristic acid, DL-Lactic acid, and 3-methyl-2-oxopentanoic. Overall, the study provides valuable insights into the metabolic changes associated with non-obese NAFLD patients and can contribute to the development of non-invasive diagnostic biomarkers for NAFLD.Publication Open Access Association of endoscopic variceal treatment with portal venous system thrombosis in liver cirrhosis: a case-control study(2022-05-01T00:00:00Z) Wang, Le; Guo, Xiaozhong; Shao, Xiaodong; Xu, Xiangbo; Zheng, Kexin; Wang, Ran; Chawla, Saurabh; BAŞARANOĞLU, METİN; Qi, Xingshun; BAŞARANOĞLU, METİNBackground: The association of endoscopic variceal treatment (EVT) with portal venous system thrombosis (PVST) in liver cirrhosis is still unclear. Methods: PVST was assessed by contrast-enhanced CT or MRI in 406 cirrhotic patients from our prospective database. Case and control groups, which are defined as patients with and without PVST, respectively, were matched at a ratio of 1:1 according to age, gender, Child-Pugh class, and MELD score. History of EVT was reviewed. Logistic regression analysis was used to identify the risk factors for PVST. Odds ratios (ORs) were calculated. Subgroup analyses were further performed in terms of degree and location of PVST. Results: Overall, 109 patients each were included in case and control groups. The case group had a significantly higher proportion of patients who had undergone EVT than the control group (53.2% versus 18.3%; p < 0.001). In detail, the case group had significantly higher proportions of patients who had undergone EVT for controlling bleeding (45.9% versus 14.7%; p < 0.001), endoscopic variceal ligation (EVL) alone (19.3% versus 9.2%; p = 0.033), and EVL combined with endoscopic cyanoacrylate glue injection (24.8% versus 5.5%; p < 0.001). EVT was independently associated with PVST (OR = 4.258; p < 0.001). In subgroup analyses, EVT remained independently associated with partial PVST (OR = 10.063; p < 0.001), complete PVST/fibrotic cord (OR = 4.889; p = 0.008), thrombosis within main portal vein (OR = 5.985; p < 0.001), and thrombosis within superior mesenteric and splenic veins (OR = 5.747; p < 0.001). Conclusions: EVT may lead to a higher risk of PVST, especially more severe PVST, in liver cirrhosis. Screening for and prophylaxis of PVST after EVT should be further explored.Publication Metadata only İÇİMİZDEKİ ÇERNOBİL(2020-01-01T00:00:00Z) Başaranoğlu, Metin; BAŞARANOĞLU, METİNPublication Metadata only Telenutrition for the management of inflammatory bowel disease: Benefits, limits, and future perspectives(2023-01-16) Coşkun M. G.; Kolay E.; BAŞARANOĞLU M.; BAŞARANOĞLU, METİN© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reservedPatients with inflammatory bowel disease (IBD) require lifelong and personalized care by a multidisciplinary healthcare team. However, the traditional medical model is not ideal for patients who require continuous close monitoring and whose symptoms may dramatically worsen between regularly scheduled visits. Additionally, close dietary follow-up and monitoring of IBD in a traditional setting are challenging because of the disease complexity, high pressure on outpatient clinics with a small number of IBD specialist dietitians, and rising incidence. Given the significant burden of IBD, there is a need to develop effective dietary management strategies. The coronavirus disease 2019 pandemic caused an unprecedented shift from in-person care to delivering health care via technological remote devices. Traditional nutrition therapy and consultation can be provided by telenutrition through remote electronic communication applications that could greatly benefit patient care. Telenutrition might be useful, safe, and cost-effective compared with standard care. It is likely that virtual care for chronic diseases including IBD will continue in some form into the future. This review article summarizes the evidence about telenutrition applications in the management of IBD patients, and we gave an overview of the acceptance and impact of these interventions on health outcomesPublication Open Access Lean and Nonobese NAFLD/NASH From a Hepatologist-s Point of View(2021-01-01T00:00:00Z) BAŞARANOĞLU, METİN; BAŞARANOĞLU, METİNPublication Metadata only Increased neuroendocrine tumours, but small colorectal cancer incidence in patients with inflammatory bowel disease treated by mesalazine(2020-06-01T00:00:00Z) BAŞARANOĞLU, METİN; Kapsigay, Mustafa; KUNDUZ, ENVER; BAŞARANOĞLU, METİN; KUNDUZ, ENVERPublication Metadata only Increased prevalence of portal vein thrombosis in patients with nonalcoholic steatohepatitis-cirrhosis due to increased proinflammatory cytokines releasing from abdominal adipose tissue(2020-02-01T00:00:00Z) Abdallah, Anas; BAŞARANOĞLU, METİNPublication Metadata only Recurrent -gloves and socks- distribution with bullous eruptions after adalimumab and infliximab treatment in a patient with Crohn-s disease(2020-05-01T00:00:00Z) Ozkan, Esin; BAŞARANOĞLU, METİN; BAŞARANOĞLU, METİNPublication Metadata only Replacing the Name of NAFLD With a Metabolic or Another Forename as Indicator of the Era of Stagnation in NASH Studies(2021-07-01T00:00:00Z) BAŞARANOĞLU, METİN; Kurtoglu, Alev; BAŞARANOĞLU, METİN